Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Epidermolysis Bullosa, Epidermolysis Bullosa Simplex
Interventions: diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 6 Months to 99 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 19 Years and older
Enrollment: 1,613 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Actinic Keratosis, Squamous Cell Carcinoma
Interventions: ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%, Vehicle gel; Drug · Other
Lead sponsor: LEO Pharma; Industry
Eligibility: Not listed
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 30
States / cities: Hot Springs, Arkansas • Fremont, California • Murrieta, California + 24 more

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Genetic Counseling and Testing YouTube Video; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia

Conditions: Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Chemotherapy Induced Alopecia
Interventions: Scalp Cooling by DigniCap; Device
Lead sponsor: George Washington University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Acne Vulgaris
Interventions: CB-03-01, Vehicle; Drug
Lead sponsor: Intrepid Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Sanford, Florida + 9 more

Conditions: Triple-Negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 93
States / cities: Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
Interventions: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E); Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 20
States / cities: Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more

Conditions: Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: MSB11022, Humira®; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Philips Healthcare; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia

Conditions: Rheumatic Diseases
Interventions: New e-prescribing interface; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 120 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Eribulin Mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more

Conditions: Skin Infection, Bacterial Infection
Interventions: Daptomycin, Brilacidin; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 1 more

Conditions: Hidradenitis Suppurativa
Interventions: Electronic Reporting, Adalimumab; Other · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Interventions: CAB-ROR2-ADC, PD-1 inhibitor; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 30 more

Conditions: Non-small Cell Lung Cancer, Glioblastoma Multiforme
Interventions: GLR2007; Drug
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Lafayette, Indiana • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more

Conditions: Breast Cancer
Interventions: CaringGuidance™ After Breast Cancer Diagnosis; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Early-stage Breast Cancer, Breast Cancer Female, Survivorship, Cancer Survivors, Transitional Care
Interventions: CCC website, Static care plan; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 21 Years to 84 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atopic Dermatitis, Eczema
Interventions: Water, Bleach, Acetic acid; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Rochester, Minnesota • Saint Paul, Minnesota

Conditions: Breast Cancer
Interventions: tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hyper-IgM Syndrome, Ectodermal Dysplasia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gynecomastia
Interventions: Zeltiq Coolsculpting System; Device
Lead sponsor: Dermatology, Laser & Vein Specialists of the Carolinas; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Mucopolysaccharidosis II, MPS II
Interventions: SB-913; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • New York, New York + 2 more

Search by objective public record fields.

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (The CLEAR Registry)

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

CARE (Chemotherapy Alopecia REduction)

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)

Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Hidradenitis Suppurativa Patient Experience With Humira Treatment

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Evaluation of GLR2007 for Advanced Solid Tumors

Facilitating Oncology Patient-Clinician Communication Via E-health Innovations

The ConnectedCancerCare Pilot Study (CCC)

The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II